comparemela.com

Page 9 - Shauna Dillon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ObsEva Announces Corporate Updates

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 27, 2022 – ObsEva .

Shauna dillonManagement incExchange commissionExchange commission onSwiss exchangeAmendment agreementSecurities purchase agreementSecurities purchaseNasdaq global select marketNote regarding forward looking statementsPrivate securities litigation reform actRisk factorsAnnual reportSina com hkHong kong

ObsEva Announces Corporate Updates

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Shauna dillonManagement incExchange commissionExchange commission onSwiss exchangeAmendment agreementSecurities purchase agreementSecurities purchaseNasdaq global select marketNote regarding forward looking statementsPrivate securities litigation reform actRisk factorsAnnual reportGlobe newswireObseva sa

Investegate |ObsEva SA Announcements | ObsEva SA: ObsEva Announces Corporate Updates

Investegate announcements from ObsEva SA, ObsEva Announces Corporate Updates

Shauna dillonManagement incExchange commissionExchange commission onSwiss exchangeObseva announces corporateAmendment agreementSecurities purchase agreementSecurities purchaseNasdaq global select marketNote regarding forward looking statementsPrivate securities litigation reform actRisk factorsAnnual reportInvestegate announcementsInvestegate company announcements

ObsEva SA: ObsEva Announces Corporate Updates

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - May 27, 2022 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and

Shauna dillonManagement incExchange commissionExchange commission onSwiss exchangeAmendment agreementSecurities purchase agreementSecurities purchaseNasdaq global select marketNote regarding forward looking statementsPrivate securities litigation reform actRisk factorsAnnual report

ObsEva SA: ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20th

United statesKarolinska institutetShauna dillonJacques donnezBrandi howardHugh taylorKristina gemzell danielssonYale school of medicineProgram in uterine fibroidsSociety of endometriosisInternational society of gynecological endocrinologyEuropean commissionDrug administrationInternational societySwiss exchangeUterine disorders congress

vimarsana © 2020. All Rights Reserved.